U.S., Sept. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07801287) titled 'Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC' on Aug. 30.
Brief Summary: This study aims to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (the combination antibody) combined with SBRT and Lenvatinib in the perioperative treatment of patients with potentially resectable intermediate-stage hepatocellular carcinoma.. The objective is to explore potential survival benefits for this population and provide patients with more effective treatment options.
Study Start Date: Sept. 01
Study Type: INTERVENTIONAL
Condition:
HCC - Hepatocellul...